Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1358-1361 , April 2009

No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles

Received 17 October 2007 ,Revised 28 March 2008 ,Accepted 28 March 2008.

References 

  1. Garcia-Velasco JA, Isaza V, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing. Fertil Steril. 2006;85:547–554
  2. Sauer MV, Paulson RJ, Lobo RA. Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors. Int J Gynaecol Obstet. 1996;52:259–262
  3. Halme J, Toma SK, Talbert LM. A case of severe ovarian hyperstimulation in a healthy oocyte donor. Fertil Steril. 1995;64:857–859
  4. ESHRE Task Force on Ethics and Law 12. Oocyte donation for non-reproductive purposes. Hum Reprod. 2007;22:1210–1213
  5. Covington SN, Gibbons WE. What is happening to the price of eggs?. Fertil Steril. 2007;87:1001–1004
  6. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–1687
  7. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril. 2007;88:237–239
  8. Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–1220
  9. Kolibianakis EM, Schultze-Mosgau A, Schroder A, van Steirteghem A, Devroey P, Diedrich , et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocytes maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887–2892
  10. Balach J, Tur R, Creus , Buxaredas R, Fabregues F, Ballesca JL, et al. Triggering of ovulation by a gonadotropin release hormone agonist in gonadotropin-stimulated cycles for prevention of ovarian hyperstimulation syndrome and multiple pregnancy. Gynecol Endocrinol. 1994;8:7–12
  11. Ricciarelli E, Sanchez M, Martinez M, Andres L, Cuadros J, Hernández ER. Impact of the GnRH antagonist in oocyte donation cycles. Fertil Steril. 2003;79:1461–1463
  12. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2003;80:1309–1314
  13. Kol SK. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1–5
  14. Tay CC. Use of gonadotropin-releasing hormone agonist to trigger ovulation. Hum Fertil (Cambridge). 2002;5:35–37
  15. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56:213–220

 E.R.H has nothing to disclose. J.L.G.-P. has nothing to disclose. E.R. has nothing to disclose.

PII: S0015-0282(08)00752-8

doi: 10.1016/j.fertnstert.2008.03.077

Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1358-1361 , April 2009

Article Tools